Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.30 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.30 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367948 | 0.79 | — | — | |
| SCHEMBL7708209 | 0.78 | HSD11B1 (0.34) | HSD11B1NR1H3NR1H2MEN1TSHR | |
| SCHEMBL37033 | 0.75 | HTR6 (0.42) | HSD11B1NR1H3NR1H2TSHR | |
| SCHEMBL962839 | 0.74 | HSD11B1 (0.41) | HSD11B1NR1H3NR1H2ABCC9ABCC8 | |
| SCHEMBL482039 | 0.74 | HSD11B1 (0.36) | HSD11B1NR1H3NR1H2ABCC9ABCC8 | |
| SCHEMBL1484104 | 0.72 | RORC (0.35) | HSD11B1NR1H3NR1H2TSHR | |
| SCHEMBL965951 | 0.71 | CA1 (0.39) | HSD11B1NR1H3NR1H2ABCC9ABCC8 | |
| SCHEMBL2437767 | 0.71 | HTR6 (0.38) | HSD11B1NR1H3NR1H2TSHR | |
| SCHEMBL217002 | 0.71 | HTR6 (0.38) | HSD11B1NR1H3NR1H2TSHR | |
| SCHEMBL51400 | 0.70 | CA1 (0.43) | HSD11B1NR1H3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539316-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-9631048-B2 | Sulfonium compounds, their preparation and use | BASF SE (DE) | 2017-04-25 | — | — | US | disclosed |
| EP-2838927-A2 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | BASF SE (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20150044509-A1 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | BASF SE (DE) | 2015-02-12 | — | — | US | disclosed |
| US-8580478-B2 | Latent acids and their use | BASF SE (DE) | 2013-11-12 | — | — | US | disclosed |
| WO-2013156509-A2 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | BASF SE (DE) | 2013-10-24 | — | — | WO | disclosed |
| EP-2539316-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20110217654-A1 | Latent acids and their use | BASF SE (DE) | 2011-09-08 | — | — | US | disclosed |
| WO-2011104127-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044509-A1 | SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE | SQOR, ACSL3, ARSA | HSD11B1 1781/4885NR1H3 261/4885GAA 3590/4885 |
| US-20110217654-A1 | Latent acids and their use | NR1H3, NR1H2, NR2E3 | HSD11B1 185/4885NR1H3 1/4885GAA 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.